1-5 of 5
Horst Lindhofer
Close
Sort by
Journal Articles

Induction of Anti-Cancer Effects by Targeting Alloreactive Intentionally Mismatched T Cells and NK Cells to Tumor Cells Using Bi-Specific Trifunctional Antibodies.

Shoshana Morecki, PhD, Horst Lindhofer, PhD, Elena Yacovlev, Yael Gelfand, MSc, Shimon Slavin, MD
Journal: Blood
Blood (2006) 108 (11): 3245.
https://doi.org/10.1182/blood.V108.11.3245.3245
Published: 2006
Journal Articles

Use of trifunctional bispecific antibodies to prevent graft versus host disease induced by allogeneic lymphocytes

Shoshana Morecki, Horst Lindhofer, Elena Yacovlev, Yael Gelfand, Shimon Slavin
Journal: Blood
Blood (2006) 107 (4): 1564–1569.
https://doi.org/10.1182/blood-2005-07-2738
Published: 2006
Journal Articles

Adoptive Immunotherapy of p53-Mutated B-CLL with a Trifunctional Antibody (Anti-CD3 x Anti-CD20) and Allogeneic Donor Lymphocyte Transfusion.

Raymund Buhmann, MD, Michael Stanglmaier, PhD, Belinda Simoes, MD, Ting Yang, MD, Peter Ruf, PhD, Horst Lindhofer, PhD, Hans-Jochem Kolb, MD, PhD
Journal: Blood
Blood (2005) 106 (11): 4823.
https://doi.org/10.1182/blood.V106.11.4823.4823
Published: 2005
Journal Articles

Impact of the lymphoma idiotype on in vivo tumor protection in a vaccination model based on targeting antigens to antigen-presenting cells

Konrad Kronenberger, Andreas Dieckmann, Michael Selmayr, John Strehl, Ulrich Wahl, Horst Lindhofer, Georg Kraal, Ralph Mocikat
Journal: Blood
Blood (2002) 99 (4): 1327–1331.
https://doi.org/10.1182/blood.V99.4.1327
Published: 2002
Journal Articles

Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody

Peter Ruf, Horst Lindhofer
Journal: Blood
Blood (2001) 98 (8): 2526–2534.
https://doi.org/10.1182/blood.V98.8.2526
Published: 2001